The company is developing a cancer immunotherapy program, which uses chimeric endocrine receptor t-cell (CER-T) technology, a new type of CAR-T.

In July 2019, Anixa announced a strategic alliance and license agreement with Cleveland Clinic for an innovative breast cancer vaccine technology.